These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 17667591

  • 1. Targeting Akt in cancer therapy.
    LoPiccolo J, Granville CA, Gills JJ, Dennis PA.
    Anticancer Drugs; 2007 Sep; 18(8):861-74. PubMed ID: 17667591
    [Abstract] [Full Text] [Related]

  • 2. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway.
    Granville CA, Memmott RM, Gills JJ, Dennis PA.
    Clin Cancer Res; 2006 Feb 01; 12(3 Pt 1):679-89. PubMed ID: 16467077
    [Abstract] [Full Text] [Related]

  • 3. Emodin negatively affects the phosphoinositide 3-kinase/AKT signalling pathway: a study on its mechanism of action.
    Olsen BB, Bjørling-Poulsen M, Guerra B.
    Int J Biochem Cell Biol; 2007 Feb 01; 39(1):227-37. PubMed ID: 17018259
    [Abstract] [Full Text] [Related]

  • 4. The phosphoinositide 3-kinase/Akt1/Par-4 axis: a cancer-selective therapeutic target.
    Goswami A, Ranganathan P, Rangnekar VM.
    Cancer Res; 2006 Mar 15; 66(6):2889-92. PubMed ID: 16540633
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Phosphatidylinositol 3-kinase/AKT pathway activation in human vestibular schwannoma.
    Jacob A, Lee TX, Neff BA, Miller S, Welling B, Chang LS.
    Otol Neurotol; 2008 Jan 15; 29(1):58-68. PubMed ID: 18199958
    [Abstract] [Full Text] [Related]

  • 7. [Drug resistance mediated by survival- and growth-promoting signaling pathways].
    Fujita N.
    Gan To Kagaku Ryoho; 2009 Apr 15; 36(4):567-71. PubMed ID: 19381028
    [Abstract] [Full Text] [Related]

  • 8. Drug discovery approaches targeting the PI3K/Akt pathway in cancer.
    Garcia-Echeverria C, Sellers WR.
    Oncogene; 2008 Sep 18; 27(41):5511-26. PubMed ID: 18794885
    [Abstract] [Full Text] [Related]

  • 9. Targeting the PI3K-Akt pathway in kidney cancer.
    Park JY, Lin PY, Weiss RH.
    Expert Rev Anticancer Ther; 2007 Jun 18; 7(6):863-70. PubMed ID: 17555396
    [Abstract] [Full Text] [Related]

  • 10. Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors.
    Porta C, Figlin RA.
    J Urol; 2009 Dec 18; 182(6):2569-77. PubMed ID: 19836781
    [Abstract] [Full Text] [Related]

  • 11. Targeting the EGFR and the PKB pathway in cancer.
    Klein S, Levitzki A.
    Curr Opin Cell Biol; 2009 Apr 18; 21(2):185-93. PubMed ID: 19216065
    [Abstract] [Full Text] [Related]

  • 12. Antineoplastic effect of proliferation signal inhibitors: from biology to clinical application.
    Bertoni E, Salvadori M.
    J Nephrol; 2009 Apr 18; 22(4):457-62. PubMed ID: 19662600
    [Abstract] [Full Text] [Related]

  • 13. Potential inhibition of PDK1/Akt signaling by phenothiazines suppresses cancer cell proliferation and survival.
    Choi JH, Yang YR, Lee SK, Kim SH, Kim YH, Cha JY, Oh SW, Ha JR, Ryu SH, Suh PG.
    Ann N Y Acad Sci; 2008 Sep 18; 1138():393-403. PubMed ID: 18837915
    [Abstract] [Full Text] [Related]

  • 14. Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
    Generali D, Fox SB, Brizzi MP, Allevi G, Bonardi S, Aguggini S, Milani M, Bersiga A, Campo L, Dionisio R, Vergoni F, Giardini R, Dogliotti L, Bottini A, Harris AL, Berruti A.
    Clin Cancer Res; 2008 May 01; 14(9):2673-80. PubMed ID: 18451231
    [Abstract] [Full Text] [Related]

  • 15. 9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-kappaB and p53 pathways.
    Guo C, Gasparian AV, Zhuang Z, Bosykh DA, Komar AA, Gudkov AV, Gurova KV.
    Oncogene; 2009 Feb 26; 28(8):1151-61. PubMed ID: 19137016
    [Abstract] [Full Text] [Related]

  • 16. Transforming growth factor beta induces apoptosis through repressing the phosphoinositide 3-kinase/AKT/survivin pathway in colon cancer cells.
    Wang J, Yang L, Yang J, Kuropatwinski K, Wang W, Liu XQ, Hauser J, Brattain MG.
    Cancer Res; 2008 May 01; 68(9):3152-60. PubMed ID: 18451140
    [Abstract] [Full Text] [Related]

  • 17. The Akt/PKB pathway: molecular target for cancer drug discovery.
    Cheng JQ, Lindsley CW, Cheng GZ, Yang H, Nicosia SV.
    Oncogene; 2005 Nov 14; 24(50):7482-92. PubMed ID: 16288295
    [Abstract] [Full Text] [Related]

  • 18. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.
    Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P.
    Curr Opin Pharmacol; 2008 Aug 14; 8(4):393-412. PubMed ID: 18721898
    [Abstract] [Full Text] [Related]

  • 19. Adiponectin signals in prostate cancer cells through Akt to activate the mammalian target of rapamycin pathway.
    Barb D, Neuwirth A, Mantzoros CS, Balk SP.
    Endocr Relat Cancer; 2007 Dec 14; 14(4):995-1005. PubMed ID: 18045951
    [Abstract] [Full Text] [Related]

  • 20. Lycopene inhibits growth of human colon cancer cells via suppression of the Akt signaling pathway.
    Tang FY, Shih CJ, Cheng LH, Ho HJ, Chen HJ.
    Mol Nutr Food Res; 2008 Jun 14; 52(6):646-54. PubMed ID: 18537129
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.